lobbying_activities: 1378983

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1378983	1295f9fe-05e5-4f04-82ac-4b90ef454df5	Q1	NOSSAMAN LLP	29846	AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")	2013	first_quarter	PHA	(H.R.800) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Pharmaceutical pedigree anti-counterfeiting legislation. Legislation pertaining to drug manufacturing shortages.	HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2013-04-18T16:48:27.007000-04:00